MODERATE-TO-SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE-TO-SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for severe eczema in toddlers
Disease control Recruiting nowThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New eczema drug TRB-061 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study checks for safety, side effects, and how the drug moves through the body. Participants receive either TRB-061 or a placebo as injectio…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: TRex Bio, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to calm severe eczema without steroids
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill tame tough eczema? a large trial aims to find out
Disease control Recruiting nowThis phase 3 trial tests whether an experimental oral drug called VC005 can reduce eczema symptoms in adults with moderate to severe atopic dermatitis. Participants are randomly assigned to receive either a low or high dose of VC005 or a placebo. The main goal is to see if more p…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New shot could tame tough eczema by calming overactive immune cells
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New shot for eczema shows promise in early trial
Disease control Recruiting nowThis study tests an experimental drug called SHR-1905 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Half will get the drug, half a placebo, and neither they nor their doctors will know who got what. The main goal is to see if the drug can reduce eczema severity…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill for eczema enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new oral drug called SYX-5219 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 149 participants will take single or multiple doses ov…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Sitryx Therapeutics Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC